Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19) is under clinical development by Blue Sky Immunotherapies and currently in Phase I for Human Papillomavirus (HPV) Associated Cancer. According to GlobalData, Phase I drugs for Human Papillomavirus (HPV) Associated Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19) overview

Oncolytic virus is under development for the treatment of human papillomavirus (HPV) associated cancer, oropharyngeal cancer, cervical cancer, human papillomavirus infections associated cervical intraepithelial neoplasia 1 (CIN1) or 2 (CIN2). It is administered through subcutaneous, intramuscular, intracervical route. The drug candidate developed based on oncolytic vaccine platform technology.

It was also under development for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

For a complete picture of Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19)’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.